Compare BBWI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | LQDA |
|---|---|---|
| Founded | 1963 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.0B |
| IPO Year | 1994 | 2020 |
| Metric | BBWI | LQDA |
|---|---|---|
| Price | $21.40 | $57.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 8 |
| Target Price | $24.93 | ★ $63.88 |
| AVG Volume (30 Days) | ★ 6.0M | 3.1M |
| Earning Date | 11-19-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $7,291,000,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $379.72 |
| Revenue Next Year | $1.69 | $17.90 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $14.28 | $22.31 |
| 52 Week High | $24.94 | $93.61 |
| Indicator | BBWI | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 67.76 |
| Support Level | $17.60 | $53.06 |
| Resistance Level | $23.86 | $63.46 |
| Average True Range (ATR) | 0.82 | 3.42 |
| MACD | -0.25 | 2.35 |
| Stochastic Oscillator | 11.69 | 91.35 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like lip.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.